Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DWP450 in Japanese Subjects with Moderate to Severe Glabellar Lines
NCT07783763Phase 3Not yet recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jan 2027
- Primary completion
- May 2028
01
Overview
A Phase 3 trial of prabotulinumtoxinA in glabellar lines, sponsored by Daewoong Pharmaceutical. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
prabotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT07783763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07783763.